Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data

被引：13

作者：

Grana, G. ^{[1
]}

机构：

[1] Cooper Univ Hosp, Dept Hematol Oncol, Camden, NJ USA

来源：

JOURNAL OF SURGICAL ONCOLOGY | 2006年 / 93卷 / 07期

关键词：

anastrozole; letrozole; exemestane; hormonal treatment; tamoxifen;

D O I：

10.1002/jso.20564

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tamoxifen is the established adjuvant treatment for postmenopausal women with hormone-sensitive early breast cancer. However, the side-effects associated with tamoxifen therapy have prompted a search for safer and potentially more effective endocrine agents. Results from randomized trials of the third-generation aromatase inhibitors, anastrozole, letrozole and exemestane, demonstrating improved efficacy compared with tamoxifen and favorable tolerability profiles, are discussed in this review.

引用

页码：585 / 592

页数：8

共 28 条

[1]

[Anonymous], 2005, Cancer facts and figures

[2] GYNECOLOGICAL MONITORING DURING TAMOXIFEN THERAPY [J].

BISSETT, D ;

DAVIS, JA ;

GEORGE, WD .

LANCET, 1994, 344 (8932) :1244-1244

[3] Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole trial [J].

Boccardo, F ;

Rubagotti, A ;

Puntoni, M ;

Guglielmini, P ;

Amoroso, D ;

Fini, A ;

Paladini, G ;

Mesiti, M ;

Romeo, D ;

Rinaldini, M ;

Scali, S ;

Porpiglia, M ;

Benedetto, C ;

Restuccia, N ;

Buzzi, F ;

Franchi, R ;

Massidda, B ;

Distante, V ;

Amadori, D ;

Sismondi, P .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5138-5147

[4] An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane [J].

Buzdar, AU ;

Robertson, JFR ;

Eiermann, W ;

Nabholtz, JM .

CANCER, 2002, 95 (09) :2006-2016

[5]

Clarke M, 1998, LANCET, V351, P1451

[6] Exemestane - A review of its use in postmenopausal women with advanced breast cancer [J].

Clemett, D ;

Lamb, HM .

DRUGS, 2000, 59 (06) :1279-1296

[7] A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer [J].

Coombes, RC ;

Hall, E ;

Gibson, LJ ;

Paridaens, R ;

Jassem, J ;

Delozier, T ;

Jones, SE ;

Alvarez, I ;

Bertelli, G ;

Ortmann, O ;

Coates, AS ;

Bajetta, E ;

Dodwell, D ;

Coleman, RE ;

Fallowfield, LJ ;

Mickiewicz, E ;

Andersen, J ;

Lonning, PE ;

Cocconi, G ;

Stewart, A ;

Stuart, N ;

Snowdon, CF ;

Carpentieri, M ;

Massimini, G ;

Bliss, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) :1081-1092

[8]

CUTULI BF, 1994, ONCOL REP, V1, P59

[9]

CUZICK J, 2005, J CLIN ONCOL, V23, P658

[10] Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study [J].

Eiermann, W ;

Paepke, S ;

Appfelstaedt, J ;

Llombart-Cussac, A ;

Eremin, J ;

Vinholes, J ;

Mauriac, L ;

Ellis, M ;

Lassus, M ;

Chaudri-Ross, HA ;

Dugan, M ;

Borgs, M ;

Semiglazov, V .

ANNALS OF ONCOLOGY, 2001, 12 (11) :1527-1532

← 1 2 3 →